메뉴 건너뛰기




Volumn 45, Issue , 2015, Pages 609-619

Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review

Author keywords

Chemotherapy; Co delivery; Drug delivery; Intraperitoneal; Nanoparticles; Ovarian cancer

Indexed keywords

CHEMOTHERAPY; DISEASE CONTROL; DRUG DELIVERY; NANOPARTICLES;

EID: 84915797130     PISSN: 09284931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msec.2014.06.002     Document Type: Article
Times cited : (62)

References (84)
  • 1
    • 84915740704 scopus 로고    scopus 로고
    • American Cancer Society [Last Medical Review: 03/21/2013 Last Revised: 02/06/2014]
    • American Cancer Society, 2013. [ http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics, Last Medical Review: 03/21/2013 Last Revised: 02/06/2014]
    • (2013)
  • 5
    • 66849097259 scopus 로고    scopus 로고
    • FIGO Committee on Gynecologic Oncology
    • FIGO Committee on Gynecologic Oncology Int. J. Gynaecol. Obstet. 105 2009 3 4
    • (2009) Int. J. Gynaecol. Obstet. , vol.105 , pp. 3-4
  • 28
    • 84915740702 scopus 로고    scopus 로고
    • or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ClinicalTrials.gov Identifier: NCT00951496, First received: August 1, 2009, Last updated: July 18 Last verified: June 2014)
    • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ClinicalTrials.gov Identifier: NCT00951496, First received: August 1, 2009, Last updated: July 18, 2014, Last verified: June 2014).
    • (2014) Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients with Stage II, Stage III
  • 62
    • 33744466541 scopus 로고    scopus 로고
    • R.S. Kerbel Science 312 2006 1171 1175
    • (2006) Science , vol.312 , pp. 1171-1175
    • Kerbel, R.S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.